




### #Hyperplex™ Cell Signaling Analysis

#### Sensitivity: The Power of Targeted Phospho-Proteomics.

Cell signaling analysis has become a key factor in understanding disease mechanisms and modulation. Unlike shotgun proteomics,

Hyperplex™ allows highly sensitive, targeted quantification of un/phosphorylated proteins along various signaling pathways from minimal sample.






#### Relevance: Expert-curated Biomarkers and Signaling Pathways.

Hyperplex<sup>™</sup> Protein Profiling is a targeted approach. The new 1,250-plex assay menu covers the most relevant 10% of the proteome including PTM. Hyperplex<sup>™</sup> allows to select markers based on 20 years of peer-reviewed biomarker discovery.

And yes, custom antibodies can be added to any panel!



Gefitinib®/Iressa® are brands of AstraZeneca. Erlotinib®/Tarceva are brands of Roche/Genentech. Sorafenib®/Nexavar® are brands of Bayer AG.


[1]: Mitsos et al. https://doi.org/10.1371/journal.pcbi.1000591



#### **#Benefits**

#### How can Hyperplex™ Protein Profiling accelerate your research?

- Sensitivity: Hyperplex<sup>™</sup> is by far the most sensitive platform on the market.
- Coverage: Hyperplex<sup>™</sup> enables the most comprehensive pathway profiling.
- Compatibility: Combine Hyperplex™ PTM analysis with soluble protein profiling (e.g. Olink®).



# #Technology

- · Electrophoresis-enhanced Western Blot.
- Proteins are barcoded.
- Up to 1,250 antibodies per sample.
- FACS readout, CV< 9%.
- Publication: <u>Treindl et al, 2016</u>

# Sample control Heatmap, table or volcano plot

# **#Sample Types**

- PBMC, cell culture, 2D/3D cells, organoids, sorted cells
- Biopsies, tissue sections, PDX
- Sample requirements: 15-40 μg of total protein



#### **#Case Studies**

#### #1: Combination Therapy


Bayer used Hyperplex™ to investigate synergies of a Regorafenib+Sorafenib combination therapy (Disease: hepatocellular carcinoma).

Samples: Biopsies from PDX mouse models (Publication: Kissel et al., 2017)



MEK1/2 - pS217/S221

JNK/SAPK - nT183/Y185 54 kDa




#### #2: Translational Oncology

Phase 1 study on tumor samples (ovarian cancer) comparing responders vs. non responders identifies EZH2 as translational biomarker. (Publication: Naskou et al, 2020)

#### #3: Biomarker Discovery

Hyperplex<sup>™</sup> was used for the discovery of clinically relevant markers of radioresistance.

(Publication: Inder at al, 2019)





# **#The Panels: Cell Signaling and Metabolism**

Reactivity	human	mouse	rat	dog	minipig	cynomolgi
ar Signaling Pathways Panels	907	889	382	303	396	359
ling Panels	567	546	234	183	240	219
gnaling pathway	110	114	54	44	60	55
eceptor signaling pathway	263	260	117	85	125	111
signaling and resistance	34	38	16	10	17	16
signaling pathway	350	337	149	116	157	144
signaling pathway	127	133	56	38	58	55
signaling pathway	132	132	60	41	60	56
gnaling pathway	590	577	248	191	249	223
Akt signaling pathway	302	298	120	96	129	119
signaling pathway	142	140	53	39	59	54
TAT signaling pathway	90	83	38	32	43	38
otein	155	153	72	55	71	70
tein coupled receptor signaling pathway	69	68	36	24	37	34
signaling pathway	114	110	49	41	49	50
lopmental Pathways	352	362	156	124	152	142
signaling pathway	81	87	40	39	45	40
ehog signaling pathway	40	38	16	13	14	15
signaling pathway	80	84	37	28	38	31
signaling pathway	38	38	20	18	21	17
eta signaling pathway	108	114	48	35	46	42
ignaling pathway	210	210	95	75	91	88
s and Metabolism	462	456	195	154	199	181
xia and HIF-1 signaling pathway	207	203	88	71	94	88
tive stress response	205	202	86	68	84	77
ascade	66	72	27	28	32	28
IAPK pathway	52	54	30	17	25	22
signaling pathway	96	92	27	25	34	33
	225	224	103	68	95	90
n signaling pathway	407	380	185	150	191	162
ne Signaling and Inflammation	270000	1000000	Wilderson .	43	110000	200 200
receptor signaling pathway and activation	119	109	53	69	57	52
receptor signaling pathway and activation	65	178 68	82 32	1000000	82	74 26
eron-gamma signaling pathway	98	94	41	26 36	27 47	38
ke receptor signaling pathway	155	135	70	61	78	65
ppa B signaling pathway	239	226	102	79	108	91
mation mediated by chemokine and cytokine signaling pathway Death Pathway Association	654	649	284	230	287	253
ignaling pathway		45		100000		
	42		22	17	24	23
osis signaling pathway	486	480	221	177	217	193
ignaling pathway	190	191	74	67	90	82
hagic processes	205	200	86	63	83	77
ignaling pathway	158	163	67	51	68	55
ar response to DNA damage stimulus	109	107	41	33	44	36
repair	(prima)					22
	57	62	24	24	27	
Pathways	657	634	277	215	283	254
signaling pathway	657 135	634 136	277 55	215 51	283 58	254 55
signaling pathway erin signaling pathway	657 135 52	634 136 48	277 55 27	215 51 19	283 58 29	254 55 27
signaling pathway	657 135	634 136	277 55	215 51	283 58	254 55









Integrin signaling pathway



# #Cancer, Neurology, Immunology

Reactivity	human	mouse	rat	dog	minipig	cynomolgi
Other Panels	944	923	397	304	405	361
Cancer Panels	448	456	196	154	197	185
Pathways in cancer	322	337	148	117	143	138
Central carbon metabolism in cancer	105	98	40	33	48	43
Acute myeloid leukemia	97	94	40	31	43	38
Bladder cancer	88	92	35	23	31	28
Breast cancer	154	162	61	54	64	63
Chronic myeloid leukemia	122	124	51	45	54	45
Colorectal cancer	137	140	65	58	67	64
Endometrial cancer	126	125	59	51	65	63
Glioma	114	114	41	34	43	41
Melanoma	114	112	47	41	48	45
Non-small cell lung cancer	133	130	54	44	53	50
Pancreatic cancer	136	141	58	50	59	54
Prostate cancer	156	156	64	55	68	65
Renal cell carcinoma	84	78	41	34	40	38
Small cell lung cancer	183	180	79	61	75	71
Thyroid cancer	58	61	28	23	23	22
Angiogenesis	228	232	101	80	107	101
Cell Cycle and Proliferation	515	519	225	183	235	218
Cell Cycle	276	291	129	106	130	116
Cell growth and proliferation	515	519	225	183	235	218
Diseases	312	315	154	124	152	137
Alzheimer disease	184	186	87	71	90	87
Hepatitis B	190	190	90	73	96	81
Huntington disease	89	96	45	36	44	42
Parkinson disease	46	42	29	18	24	23
Immune Processes	380	356	157	114	152	132
Innate immune response	80	64	31	21	26	20
Inflammatory response	133	125	54	40	55	43
Immune response	557	528	236	182	241	212
Leukocyte migration	41	39	22	14	19	17
Neutrophil degranulation	51	42	23	16	23	22
Response to virus	197	199	85	64	82	71
T Cell Maturation	146	148	66	55	64	60
T cell differentiation	116	119	50	41	47	43
Thymus development	38	37	22	18	21	21
Other Processes	693	681	292	229	295	266
Response to drug	202	194	90	68	79	72
Cell migration	233	222	99	81	106	95
Platelet	151	140	72	48	73	65
Transcription and gene expression	474	465	197	157	199	176
Protein ubiquitination	128	137	57	49	61	55
Pathway Activity Panels	242	217	87	60	97	87
Core Druggable Pathway Panel	90	86	37	23	43	39
Extended Druggable Pathway Panel	184	171	70	45	77	69
Full Druggable Pathway Panel	242	217	87	60	97	87
mTOR Pathway	119	111	39	29	47	42
PI3K / AKT Pathways	166	146	54	43	64	58

validated species

Diseases

panels

Customize
your panel
Full Druggable Pathway
mTOR Pathway
PI3K / AKT Pathways






RAS / RAF / ERK Pathways



# #Assay Configurator: Customize your panel

#### Cell Signaling Research: Just have it your way!

- Quantify up to 12,50 proteins per sample.
- Profile 50+ signaling pathways in one go
- Customizable for every project
- Freedom to add custom antibodies



The mTOR pathway panel - one of 50 validated panels

#### **#How to order?**

#### Cell Signaling: Accelerate your research with just a few clicks!

- Download the assay configurator here
- Select one or more species
- Select pathway activity panels
- Select druggable pathways
- Save the file and e-mail to <a href="mailto:hello@assay-engineers.com">hello@assay-engineers.com</a>
- Get your cost estimate within 2 days.

# Download Hyperplex Assay Configurator

#### **#Talk to a scientist!**

#### Schedule a web meeting with an expert

AssayEngineers GmbH

Berlin, Germany

Europe +49 441 3043 4267

US +1 (617)500-8221

www.assay-engineers.com

E-mail: <u>hello@assay-engineers.com</u>

